Lucid Diagnostics (LUCD) Registration Filing summary

Company overview and business model

• Commercial-stage diagnostics company focused on early detection of esophageal precancer and cancer in GERD patients, with flagship products EsoGuard (DNA test) and EsoCheck (cell collection device).

• Products are based on patented technology licensed from Case Western Reserve University and target a large at-risk population.

• EsoGuard and EsoCheck are designed to provide accurate, non-invasive, patient-friendly testing for early detection of esophageal adenocarcinoma and Barrett's Esophagus.

• The company is a subsidiary of PAVmed, which controls a majority of the voting power.

Financial performance and metrics

• Raised approximately $44.3 million in March 2024 and $11.6 million in May 2024 through private placements of Series B and Series B-1 Convertible Preferred Stock.

• Has incurred operating losses since inception and has not generated significant revenues to date.

• There is substantial doubt about the company's ability to continue as a going concern, as noted by its independent auditor.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of shares by selling stockholders; all proceeds go to selling stockholders.

• Proceeds from prior private placements were used for general corporate purposes and to fund operations.